This article was originally featured at Warrior Trading News.
If you look in the biotech space, some of the biggest conversations are revolving around some of the stocks that are falling today. However, there’s a reason there’s so much conversation about this. While the untrained eye may see dying stocks, many investors are seeing emerging opportunities. Here are a few great examples…
MannKind Is Down Nearly 10%
MannKind Corporation (NASDAQ: MNKD)
MannKind stock is falling hard today. After a bullish run that’s lasted for some time now, it seems as though the stock has hit resistance; falling like a loose brick in a hurricane. However, I’m not too concerned about today’s declines. Although I always like to see growth, I understand opportunities as well; and this is an opportunity. The bottom line is that MannKind is likely to grow throughout the end of the year as they start to market Afrezza. Physicians have already weighed in saying that they plan on using Afrezza in the future. And for MNKD, the buck doesn’t stop at the inhaled insulin. The company has openly announced that they are testing technosphere in other applications. So, who knows what injection only medication will soon have an inhaled option. All in all, today’s declines simply make the stock more appealing to me because now it’s possible to get in on the gains at a lower cost.
Aoxing Pharmaceutical Company Is Down More Than 13%
Aoxing Pharmaceutical Company Inc (NYSEMKT: AXN)
Aoxing Pharmaceutical Company stock soared on Monday as investors anticipated the big news from the company in yesterday’s announcement at the New York Stock Exchange. Unfortunately however, the news must not have been all that big because there’s not a peep in the news outlets or on the known blogs about it…it just seems like the entire topic fell off the map. Nonetheless, it may have been the news that caused the big news, but investors were ready. They know the value the company brings to the table and they know that in the long run, AXN is likely to grow. So, what they’re seeing in the decline is a 13%+ discount on a gaining opportunity.
RXi Pharmaceuticals Is Down over 6%
RXi Pharmaceuticals Corp (NASDAQ: RXII)
RXi Pharmaceuticals is also down in a pretty big way today. After climbing on the news of two USPTO Notices of Allowance, it seems as though the stock is taking a break today. However, today’s declines are like a diamond in the rough. In my opinion, there’s no reason we should see losses happen for a long term period; instead, we’re likely to see gains. So, once again, investors aren’t upset, they’re seeing it as an opportunity to get in on the gains for a cost that’s 6% lower.
Do You Know Of Any Others?
Do you know of any others that are presenting opportunities through declines? If so, let us know in the comments below!